Company: ARMP
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001104659-25-077648
Chunk: 5

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: S-3
Chunk 5
---
 Securities and Exchange Commission, or the SEC, using a “shelf”
registration process. Under this shelf registration process, we may offer and sell, either individually or in combination, in one or more
offerings, any combination of the securities described in this prospectus, for total gross proceeds of up to $100,000,000.

This prospectus provides you
with a general description of the securities we may offer. Each time we offer securities under this prospectus, we will provide a prospectus
supplement that will contain more specific information about the terms of those securities and the offering. We may also authorize one
or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. We may also
add, update or change in the prospectus supplement (and in any related free writing prospectus that we may authorize to be provided to
you) any of the information contained in this prospectus or in the documents that we have incorporated by reference into this prospectus.
We urge you to carefully read this prospectus, any applicable prospectus supplement and any related free writing prospectus, together
with the information incorporated herein by reference as described under the headings “Where You Can Find More Information”
and “Incorporation of Certain Information by Reference” before buying any of the securities being offered.

<div align='center'>1

SUMMARY</div>

The following summary highlights
information contained elsewhere in this prospectus or incorporated by reference herein and does not contain all the information that may
be important to purchasers of our securities. You should carefully read this prospectus, all documents incorporated by reference, any
prospectus supplement and any related free writing prospectus, and the additional information described under the caption “Where
You Can Find More Information” in this prospectus, before buying any of the securities being offered. References in this prospectus
to “Armata,” the “Company,” “we,” “us” and “our” refer to Armata Pharmaceuticals, Inc.
and its subsidiaries, on a consolidated basis, unless the context requires otherwise.

Our Company

We
are a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for
the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using our proprietary bacteriophage-based technology.
We have completed three Phase 2 clinical trials to date. We see bacteriophages as a potentially safer and effective alternative to antibiotics
and an essential response to the growing